FDA Approves Once-Weekly YUVIWEL® (navepegritide) for . . . “The approval of once-weekly YUVIWEL is a major step forward in the treatment of children with achondroplasia, giving physicians for the first time the option of prescribing a once-weekly medicine backed by compelling efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled clinical trials,” said Carlos A Bacino, MD, FACMG, Professor of Molecular
Approval Label_219164Orig1s000lbl YUVIWEL is a C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses (1) This indication is approved under accelerated approval based on an improvement in annualized growth velocity Continued approval for this indication may be contingent upon verification and description of clinical
Official HCP site for YUVIWEL | YUVIWEL® (navepegritide) Introducing the first and only FDA-approved, once-weekly treatment for use in children with achondroplasia 1 Discover what could be in reach YUVIWEL is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses 1 See full Indication for accelerated approval below
Yuviwel: Uses, Dosage, Side Effects, Warnings - Drugs. com Yuviwel is used to increase linear growth in children 2 years and older with achondroplasia with open epiphyses It is given once-weekly by subcutaneous injection Learn about side effects, the mechanism of action, and administration
Yuviwel for Achondroplasia - WebMD Yuviwel increased growth rate across ages and genders However, the treatment difference between Yuviwel and placebo was larger in children aged 5 years or older than in those younger than 5 years
Navepegritide (Yuviwel®) for Children with Achondroplasia . . . Navepegritide (Yuviwel®) for Children with Achondroplasia: New Drugs and Therapeutics Written by Anna Ryabets-Lienhard, DO Edited by Neha Patel, DO and Emily Breidbart, MD On February 27th, 2026, the FDA approved Navepegritide (Yuviwel®), a C-natriuretic peptide (CNP) analog prodrug developed by Ascendis Pharmaceuticals using TransCon® CNP technology 1 The once‑weekly subcutaneous therapy
Once-Weekly Treatment Approved for Achondroplasia in Kids The FDA approved navepegritide (Yuviwel) for children ages 2 and older with achondroplasia, the most common form of dwarfism, developer Ascendis Pharma announced on Friday The prodrug of C-type